Landos Biopharma, Inc.
Landos Biopharma, Inc. (LABP) Stock Overview
Explore Landos Biopharma, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
71.7M
P/E Ratio
-9.48
EPS (TTM)
$-4.00
ROE
-0.55%
LABP Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Landos Biopharma, Inc. (LABP) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of $1.45.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -9.48 and a market capitalization of 71.7M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Company Profile
Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. The company's lead product candidate in development include omilancor, a gut-restricted oral therapeutic candidate that targets lanthionine synthetase C-like protein 2 (LANCL2) for the treatment of ulcerative colitis (UC), Crohn's disease (CD), and eosinophilic esophagitis; NX-13, a gut-restricted oral therapeutic that targets NOD-like receptor X1 (NOD-like), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines for UC and CD; and LABP-104, an orally-active and systemically bioavailable small molecule therapeutic candidate that targets LANCL2 agonist for the treatment of systemic lupus erythematosus and rheumatoid arthritis (RA). Its preclinical candidates in development include LABP-66 is an oral and small molecule NOD-like pathway agonist for the treatment of multiple sclerosis and Alzheimer's disease; LABP-69, an oral PLXDC2 agonist for the treatment of diabetic nephropathy and RA; LABP-73, an oral and small molecule NLRX1 pathway agonist in development for the treatment of asthma and chronic obstructive pulmonary disease; and LABP-111, an oral and small molecule LANCL2 pathway agonist for the treatment of nonalcoholic steatohepatitis and type 1 diabetes. The company was incorporated in 2017 and is headquartered in Blacksburg, Virginia.
Gregory Oakes
19
1800 Kraft Drive, Blacksburg, VA
2021